Business Context and Reporting Period
Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2006
Business Overview: Cardinal Health operates as a leading provider of healthcare products and services. Effective the first quarter of fiscal 2007, the company reorganized its operations into five reportable segments: Healthcare Supply Chain Services (Pharmaceutical and Medical), Clinical Technologies and Services, Pharmaceutical Technologies and Services, and Medical Products Manufacturing. The company is currently subject to ongoing investigations by the SEC and the U.S. Attorney's Office regarding accounting practices.
Key Financial Metrics
| Metric (in millions, except per share) | Q3 2006 | Q3 2005 |
|---|---|---|
| Revenue | $21,356.7 | $19,237.2 |
| Gross Margin | $1,298.9 | $1,194.2 |
| Operating Earnings | $463.7 | $376.7 |
| Net Earnings | $270.7 | $228.3 |
| Diluted EPS | $0.66 | $0.53 |
| Cash from Operating Activities | $718.3 | $724.6 |
| Cash and Equivalents (End of Period) | $1,609.6 | $1,976.3 |
| Total Assets | $23,431.2 | $23,374.1 |
| Total Liabilities | $15,010.1 | $14,883.4 |
Note: Total Liabilities calculated as Total Assets minus Total Shareholders' Equity.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 11% year-over-year, driven primarily by a 12% increase in the Healthcare Supply Chain Services - Pharmaceutical segment, which accounts for approximately 85% of total revenue. Growth was fueled by bulk and non-bulk retail chain customers and mail order business.
- Profitability: Operating earnings rose 23% to $463.7 million. This increase was significantly aided by a $36.8 million reduction in equity-based compensation expense compared to the prior year.
- Discontinued Operations: Loss from discontinued operations increased significantly to $29.6 million (from $9.2 million), primarily due to impairment charges and losses on the sale of the Healthcare Marketing Services (HMS) and Intercare Pharmaceutical Distribution (IPD) businesses.
- Special Items: Total special items increased to $24.3 million from $21.3 million. This included $13.4 million in restructuring costs and $7.2 million in net litigation settlements (including a $11.5 million DuPont settlement offset by $7.3 million in antitrust recoveries).
- Product Recall: The company recorded a $13.5 million charge related to the Class 1 recall of the Alaris SE pump due to a "key bounce" risk.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
Management expects to complete a combined $2 billion share repurchase program during fiscal 2007 and 2008. The company believes it has adequate capital resources to fund anticipated capital expenditures and debt service. No specific financial guidance for the full fiscal year was provided in this text, though management noted that interim results are not necessarily indicative of full-year results.
Risks and Contingencies
- SEC and U.S. Attorney Investigations: The company is under formal investigation regarding accounting and financial reporting matters. An agreement-in-principle for a settlement involving a $35 million penalty has been reached with the SEC staff, though final terms are not guaranteed.
- Shareholder Litigation: Multiple class action lawsuits (securities and ERISA) are pending. The company cannot predict the outcome or potential loss range, which could be material.
- Product Liability: The Alaris SE pump recall (Class 1) resulted in a $13.5 million charge. While currently deemed immaterial to overall operations, further remedial actions could have a material impact.
- Regulatory Scrutiny: The company faces ongoing inquiries from the FTC, New York Attorney General, and Illinois Attorney General regarding industry practices and Medicaid claims.
Unusual Items
- Equity-Based Compensation: A significant decrease in equity-based compensation expense ($45.0 million in Q3 2006 vs. $81.8 million in Q3 2005) positively impacted operating earnings. The prior year included a large charge related to Stock Appreciation Rights (SARs) granted to the former CEO.
- Segment Realignment: The company reorganized its reporting segments effective Q1 2007, requiring reclassification of prior period data.
Investor Verification Checklist
- Settlement Finality: Verify the final status and terms of the SEC settlement agreement and the $35 million penalty reserve.
- Recall Impact: Monitor the FDA's resolution of the Alaris SE pump recall and any potential for additional charges beyond the $13.5 million recorded.
- Litigation Exposure: Assess the potential financial impact of pending shareholder class actions and ERISA lawsuits, as the company states losses are currently indeterminable.
- Share Repurchase Execution: Track the progress of the $2 billion share repurchase program and its impact on cash flow and earnings per share.
- Discontinued Operations: Confirm the closing of the HMS and IPD business sales and the finalization of associated impairment charges.